Publications by authors named "Geoff Hale"

Claim this Profile
A
A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis.
Catherine A Lawson, Rachel Harry, Bridget Griffiths, Geoff Hale, Herman Waldmann

Immunother Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Living in LALA land? Forty years of attenuating Fc effector functions.
Geoff Hale

Immunol Rev· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors.
Geoff Hale, Jelle De Vos, Alastair Douglas Davy, Koen Sandra, Ian Wilkinson

MAbs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors.
Geoff Hale, Alastair Douglas Davy, Ian Wilkinson

MAbs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.
Ian Wilkinson, Geoff Hale

MAbs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dry-compression packing of hydroxyapatite nanoparticles within a flat cuboid chromatography device and its use for fast protein separation.
Raja Ghosh, Geoff Hale, Yves Durocher, Paul Gatt

J Chromatogr A· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-engineered antibodies with immune effector functions completely abolished.
Ian Wilkinson, Stephen Anderson, Jeremy Fry, Louis Alex Julien, David Neville, Geoff Hale

PLoS One· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tackling bovine TB.
Mark Jones, Fiona Dalzell, Richard Edwards, Phill Elliott, Geoff Hale

Vet Rec· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrafast Separation and Analysis of Monoclonal Antibody Aggregates Using Membrane Chromatography.
Pedram Madadkar, Umatheny Umatheva, Geoff Hale, Yves Durocher, Raja Ghosh

Anal Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.
Laura Jardine, Amy Publicover, Venetia Bigley, Geoff Hale, Kim Pearce

Br J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry.
Alice Harrison, Zhe Liu, Schona Makweche, Kevin Maskell, Hong Qi, Geoff Hale

J Pharm Biomed Anal· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.
Chantal Kuhn, Sylvaine You, Fabrice Valette, Geoff Hale, Peter van Endert

Sci Transl Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
Geoff Hale, Peppy Rebello, Ibrahim Al Bakir, Emma Bolam, Pawel Wiczling

J Clin Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Ronjon Chakraverty, Guillermo Orti, Michael Roughton, Jun Shen, Adele Fielding, Geoff Hale

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel strategy to reduce the immunogenicity of biological therapies.
Jennifer Somerfield, Grant A Hill-Cawthorne, Andrew Lin, Michael S Zandi, Claire McCarthy, Geoff Hale

J Immunol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.
Kathryn Chapman, Nick Pullen, Lee Coney, Maggie Dempster, Laura Andrews, Geoff Hale

MAbs· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Bart Keymeulen, Sophie Candon, Samira Fafi-Kremer, Anette Ziegler, Marianne Leruez-Ville, Geoff Hale

Blood· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Karin C Straathof, Kanchan Rao, Matthias Eyrich, Geoff Hale, Prudence Bird

Lancet· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.
Alice R Lorenzi, Alexandra M Clarke, Tom Wooldridge, Herman Waldmann, Geoff Hale

Arthritis Rheum· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Andy C Rawstron, Giles Laycock-Brown, Geoff Hale, Faith E Davies, Gareth J Morgan

Haematologica· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab.
Peter A von dem Borne, Floor Beaumont, C W J Ingrid Starrenburg, Machteld Oudshoorn, Geoff Hale

Haematologica· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-size-based membrane chromatographic separation and analysis of monoclonal antibody aggregates.
Lu Wang, Geoff Hale, Raja Ghosh

Anal Chem· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo.
Tanzina Haque, Ingolfur Johannessen, Dilani Dombagoda, Chandrya Sengupta, David M Burns, Geoff Hale

J Infect Dis· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic antibodies--delivering the promise?
Geoff Hale

Adv Drug Deliv Rev· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Sudhir Tauro, Charles Craddock, Karl Peggs, Gulnaz Begum, Premini Mahendra, Geoff Hale

J Clin Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis